Basal Cell Carcinoma Masquerading as a Dermoid Cyst and Bursitis of the Knee

Kristyna Gleghorn, MD; Kyle Kaltwasser, MD; Keith D. Wagner, MS; Skyler White, MD; Jason Hirshburg, MD; Brandon P. Goodwin, MD

PRACTICE POINTS

- This case highlights an unusual presentation of basal cell carcinoma masquerading as bursitis.
- Clinicians should be aware of confirmation bias, especially when multiple physicians and specialists are involved in a case.
- When the initial clinical impression is not corroborated by objective data or the condition is not responding to conventional therapy, it is important for clinicians to revisit the possibility of an inaccurate diagnosis.

Basal cell carcinoma (BCC) is the most common malignant skin cancer diagnosed in the United States. We present the case of a 67-year-old man whose knee pain and tumor of 2 years' duration was initially diagnosed as a dermoid cyst and bursitis. Dermatology referral confirmed a delayed diagnosis of BCC. This case provides insight into the range of BCC presentations and reminds clinicians to consider BCC when the differential diagnosis includes a dermoid cyst and bursitis.

Cutis. 2019;103:288-289.

Basal cell carcinoma (BCC) is the most frequently diagnosed skin cancer in the United States. It develops most often on sun-exposed skin, including the face and neck. Although BCCs are slow-growing tumors that rarely metastasize, they can cause notable local destruction with disfigurement if neglected or inadequately treated. Basal cell carcinoma arising on the legs is relatively uncommon.^{1,2} We present an interesting case of delayed diagnosis of BCC on the left knee due to earlier misdiagnoses of a dermoid cyst and bursitis.

Case Report

A 67-year-old man with no history of skin cancer presented with a painful growing tumor on the left knee of approximately 2 years' duration. The patient's primary care physician as well as a general surgeon initially diagnosed it as a dermoid cyst and bursitis. The nodule failed to respond to conservative therapy with nonsteroidal antiinflammatory drugs and continued to grow until it began to ulcerate. Concerned about the possibility of septic arthritis, the patient's primary care physician referred him to the emergency department. He was subsequently sent to the dermatology clinic.

On examination by dermatology, a 6.3×4.4 -cm, tender, mobile, ulcerated nodule was noted on the left knee (Figure 1A). No popliteal or inguinal lymph nodes were palpable. Basal cell carcinoma, squamous cell carcinoma, or atypical infection (eg, *Leishmania*, deep fungal, mycobacterial) was suspected clinically. The patient underwent a diagnostic skin biopsy; hematoxylin and eosin–stained sections revealed lobular proliferation of basaloid cells with peripheral palisading and central tumoral necrosis, consistent with primary BCC (Figure 2).

Given the size of the tumor, the patient was referred for Mohs micrographic surgery and eventual reconstruction by a plastic surgeon. The tumor was cleared after 2 stages of Mohs surgery, with a final wound size of 7.7×5.4 cm (Figure 1B). Plastic surgery later performed

RELATED ARTICLE ONLINE

Approach to Management of Giant Basal Cell Carcinomas

>> bit.ly/2DCg19W

From the Department of Dermatology, University of Texas Medical Branch, Galveston.

The authors report no conflict of interest.

Correspondence: Keith D. Wagner, MS, 301 University Blvd, Galveston, TX 77555 (Kedwagne@utmb.edu).



FIGURE 2. A, Lobular proliferation of basaloid cells with peripheral palisading and central tumoral necrosis. A, Dermal fibrosis and chronic inflammation were present (H&E, original magnification ×40). B, Proliferation of atypical basaloid cells with hyperchromatic nuclei, scant cytoplasm, scattered mitoses, tumoral necrosis, and peripheral palisading. Intratumoral and extratumoral mucin deposition was present (H&E, original magnification ×100).

a gastrocnemius muscle flap with a split-thickness skin graft (175 cm²) to repair the wound.

Comment

Exposure to UV radiation is the primary causative agent of most BCCs, accounting for the preferential distribution of these tumors on sun-exposed areas of the body. Approximately 80% of BCCs are located on the head and neck, 10% occur on the trunk, and only 8% are found on the lower extremities.¹

Giant BCC, the finding in this case, is defined by the American Joint Committee on Cancer as a tumor larger than 5 cm in diameter. Fewer than 1% of all BCCs achieve this size; they appear more commonly on the back where they can go unnoticed.² Neglect and inadequate treatment of the primary tumor are the most important contributing factors to the size of giant BCCs. Giant BCCs also have more aggressive biologic behavior, with an increased risk for local invasion and metastasis.³ In this case, the lesion was larger than 5 cm in diameter and occurred on the lower extremity rather than on the trunk.

This case is unusual because delayed diagnosis of BCC was the result of misdiagnoses of a dermoid cyst and bursitis, with a diagnostic skin biopsy demonstrating BCC almost 2 years later. It should be emphasized that early diagnosis and treatment could prevent tumor expansion. Physicians should have a high degree of suspicion for BCC, especially when a dermoid cyst and knee bursitis fail to respond to conservative management.

REFERENCES

- Pearson G, King LE, Boyd AS. Basal cell carcinoma of the lower extremities. Int J Dermatol. 1999;38:852-854.
- Arnaiz J, Gallardo E, Piedra T, et al. Giant basal cell carcinoma on the lower leg: MRI findings. J Plast Reconstr Aesthet Surg. 2007;60:1167-1168.
- Randle HW. Giant basal cell carcinoma [letter]. Int J Dermatol. 1996;35:222-223.

Copyright Cutis 2019. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.